Dr. Dirk Thye has over 20 years of experience in biotechnology company creation, drug discovery, research and development, and executive leadership. Dr. Thye is a founder of seven companies (three in small molecule drugs, three in CRO services, one in medical devices), five of which were sold with excellent returns for investors.  He has operated as CEO in eight companies (including two when hired externally) and CMO/Head of Clinical Development in several others.  

Several of the drug development programs led by Dr. Thye have achieved FDA approval and he has worked in a variety of therapeutic areas such as infectious diseases, antibody/ADC discovery, oncology, inflammation, metabolic disease and others.

Dr. Thye’s corporate financing endeavors include private, IPO and follow-on public financings resulting in over $350 million of company investment and successful exits generating billions of dollars in shareholder value.  

Dr. Thye’s educational background includes a BA in Molecular Biology from UC Berkeley, an MD from UCLA, and residency in Internal Medicine at Stanford University. 

‍